Italy
Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium
(Lu-177)-based, and Yttrium (Y-90)-based), by Indication
(Gastroenteropancreatic Neuroendocrine Tumor), and by Distribution Channel
(Hospital Pharmacies and Retail Pharmacies), was valued at US$ 3.6 million in
2019 and is expected to exhibit a CAGR of 9.2%over the forecast period
(2019-2027), as highlighted in a new report published by.
Increasing drug approvals by
regulatory bodies are expected to drive the Italy peptide receptor radionuclide
therapy market growth over the forecast period. For instance, in 2018, Novartis
received U.S FDA approval for lutetium (177Lu) oxodotreotide (Lutathera) for
treatment of somatostatin receptor positive gastroenteropancreatic
neuroendocrine tumors (NETs) (GEP-NETs). Furthermore, rising number of cancer
cases in Italy is a major factor driving growth of the peptide receptor
radionuclide therapy (PRRT) market in the country. For instance, according to
European Union statistics related to cancer, in 2015, about 33,851 number of
deaths were recorded due to lung cancer in Italy.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3139
This contributed to around 8% in
total Europe region, in which the share of all deaths attributed to lung cancer
was 7.2 % among men, more than double the share (3.4%) recorded for women in
Europe region.
Moreover, according to the WHO,
in 2018, a total number of 40,9,808 cancer cases were recorded in Italy, which
included prostate cancer, lung cancer, bladder cancer, colorectal cancer,
breast cancer, and other type of cancers.
Browse 9 Market Data Tables and
12 Figures spread through 64 Pages and in-depth TOC on 'Italy Peptide Receptor
Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based, and
Yttrium (Y-90)-based), by Indication (Gastroenteropancreatic Neuroendocrine
Tumor), and by Distribution Channel (Hospital Pharmacies and Retail Pharmacies)
– Italy Forecast to 2027'
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/italy-peptide-receptor-radionuclide-therapy-market-3139
Key Takeaways of the Italy
Peptide Receptor Radionuclide Therapy (PRRT) Market:
The Italy Peptide Receptor
Radionuclide Therapy (PRRT) Market is expected to exhibit a CAGR of 9.2% over
the forecast period (2019–2027) owing to increasing regulatory approvals and
incidence of cancer
Among drug type, the Lutetium
(Lu-177)-based segment is expected to account for a major revenue share by
2027, owing to increasing strategic acquisitions by key players for expanding
their drug portfolio. For instance, in 2017, Novartis acquired Advanced
Accelerator Applications. With this acquisition, Novartis has expanded its
product offering in the neuroendocrine business, through which the company
offers the Lutetium (Lu-177)-based drug.
Major player operating in the
Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is Novartis
International AG.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3139
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment